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determine the 1-year clinical follow-up in patients treated with the
bioabsorbable polymer-coated everolimus-eluting SYNERGY stent in
daily clinical routine.
METHODS All consecutive patients treated with the SYNERGY stent at
University and Hospital Fribourg, La Tour Hospital Geneva and the
University Hospital of Bern between December 2012 and June 2014
were prospectively included in the SWEET registry (SWiss Evaluation
of bioabsorbable polymer-coated Everolimus-eluting coronary sTent).
Clinical follow-up was performed at 1 year. The primary endpoint was
the Academic Research Consortium (ARC) deﬁned device-oriented
composite of cardiac death (CD), myocardial infarction of the target
vessel (TV-MI) and clinically indicated target lesion revascularization
(CI-TLR) at 1 year.
RESULTS One thousand patients were included in the SWEET reg-
istry. Intermediate analysis was performed in the ﬁrst 820 patients
(1289 lesions) in whom 1-year follow-up was available. Mean age
was 6811 years and 73% (n¼569) of patients were men. Diabetes
mellitus was present in 22% (n¼178) and a history of previous
myocardial infarction in 18% (n¼147) of patients. Acute Coronary
Syndrome was the indication for stent implantation in 55% (n¼451)
of cases of which 22% (n¼184) presented with STEMI. Median (25th-
75thpercentile) SYNTAX score was 13 (7-21). Left main treatment was
performed in 4% (n¼30) and saphenous vein graft interventions in
3% (n¼22) of patients. The primary endpoint occurred in 9.3%
(n¼76) of patients at 1 year (Figure 1). CD was 4.9% (n¼40) and TV-
MI occurred in 2.7% (n¼22) of patients. CI-TLR was performed in
4.0% (n¼33) of patients. The ARC-deﬁned patient-oriented com-
posite end point (all-cause mortality, any myocardial infarction, any
revascularization) occurred in 15.2% (n¼125) of patients at 1 year.
ARC-deﬁned deﬁnitive stent thrombosis occurred in 14 patients
(1.7%) within the ﬁrst year after stent implantation (early: 1.6%
[n¼13], late 0.1% [n¼1]).
CONCLUSIONS The bioabsorbable polymer-coated thin strut ever-
olimus-eluting SYNERGY stent yields a favorable safety and efﬁcacy in
daily clinical practice.
CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS All-Comer, Bioabsorbable polymer, Everolimus-eluting
stentsTCT-588
Primary results of 2 years clinical investigation from en-ABL e-registry
using novel abluminal coated sirolimus eluting stent with bio-degradable
polymer matrix
Subhash Chandra,1 Sameer Dani,2 Prathap K. Natarajapillai,3
Devang M. Desai,4 Rashmit Pandya,2 Manish I. Doshi,5
Prakash N. Sojitra5
1B L Kapoor Memorial Hospital, New Delhi, India; 2Lifecare Institute of
Medical Sciences and Research, Ahmedabad, India; 3meditrina
Hospital, Kollam, Kerala; 4Mahavir Hospital, Surat, India; 5Envision
Scientiﬁc Private Limited, Surat, India
BACKGROUND Newer generation of drug eluting stents (DES) has
attempted to improve safety using abluminal sirolimus drug de-
livery with biodegradable polymers matrix. Abluminus is siroli-
mus eluting stent with biodegradable polymer matrix coated on
abluminal stent and parts balloon surface. The aim of en-ABL
e-registry is to capture long term clinical data of the Abluminus by
evaluation of safety and efﬁcacy in large population in routine
clinical practice.
METHODS The study is designed for all-comers by the prospective
method in 3000 patients in India. The data was divided in 3 sub-set
of patient; diabetic (n¼300), MVD (n¼200) and long lesion (n¼200)
subsets. Primary endpoint was major adverse cardiac events
(MACE); deﬁned as composite of cardiac death, myocardial infarc-
tion (MI), cardiac / non-cardiac death, target lesion revascularization
(TLR) and target vessel revascularization (TVR) at 12 months. Major
secondary endpoints were stent thrombosis (deﬁnite and probable
according to ARC conditions) as acute, sub-acute and late
thrombosis.
RESULTS We evaluated 1026 prospective patients 1342 devices and
corresponding 1229 lesions. Mean age of population was 56.21 
10.63%, 81.77% were male, 36.65% patients were diabetic, small
vessel < 2.5 mm were 49.87% and long lesion > 28 mm were 50.12%.
Individual time domain % MACE are reported in table 1. One acute and
one sub-acute stent thrombus events was reported.
Table 1. Individual adverse events (%) at different time pointsFollow-up 1 month 3 months 9 months 12 months 24 monthsPatients – follow-up 1020 963 798 692 157Angiographic follow-up – – 99 – –MACE 0.10 0.19 1.35 0.1 0.1Death 0 0 0 0 0Cardiac death 0 0 0 0 0MI 0 0 0 0 0TVR/TLR 0.1 0.19 1.35 0.1 0.1CONCLUSIONS Interim analysis has revealed a MACE rate 1.64% at
9 month follow-up and 2 events of stent which remains unchanged
at 2 year follow-up. The data suggests safety and efﬁcacy of DES in
routine clinical practice. Further data will be presented during
conference.
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BACKGROUND The inﬂuence of diabetes mellitus (DM) on the clinical
outcomes after PCI for the multi-vessel coronary artery disease (CAD)
using drug eluting stent (DES) were not well deﬁned to date.
METHODS We evaluated the clinical outcomes after PCI using DES for
multi-vessel CAD in patients with or without DM. From January 2003
to December 2013, a total of 5057 patients underwent PCI for the
multi-vessel CAD with (n¼1738) or without (n¼3319) DM were
included. The primary outcome was the incidence of major adverse
